The New WHO Classification of Lung Tumors

Lung Cancer Biomarker Testing Patterns Varied Widely in Japan

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication

New FDA Commissioner Confirmed

Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program

NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During Social Media Event

FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur

NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors